Clinical Trials on Lymphoma in Japan

Total 234 results

Kyowa Kirin Co., Ltd.

Completed

Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL

Adult T-Cell Leukemia and Lymphoma (ATL) | Adult Peripheral T-Cell Lymphoma (PTCL)

Japan
Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma

Adult T-cell Leukemia-lymphoma

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia

Japan
GlaxoSmithKline

Completed

Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular

Japan
GlaxoSmithKline

Completed

Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma

Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic

Japan
Gilead Sciences

Completed

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Follicular Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Indolent Non-Hodgkin Lymphoma | Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)

Japan
Novartis Pharmaceuticals

Terminated

Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma

Leukemia-Lymphoma, Adult T-Cell | Cutaneous T-Cell Lymphoma

Japan
Celgene

Completed

A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

Peripheral T-cell Lymphoma | Adult T-cell Leukemia-Lymphoma

Japan
Kite, A Gilead Company

Recruiting

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (JKART-1)

Relapsed/Refractory Mantle Cell Lymphoma | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Japan
Takeda

Completed

Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

Peripheral T Cell Lymphoma | Pediatric Hodgkin Lymphoma

Japan
Takeda

Completed

Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma

Japan
Novartis

Completed

LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma

Cutaneous T-Cell Lymphoma | Tumors

Japan
Japan Clinical Oncology Group
Ministry of Health, Labour and Welfare, Japan

Completed

A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)

Lymphoma | Adult T-cell Leukemia

Japan
Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Relapsed or Refractory Diffuse Large B-cell Lymphoma

Japan
Celgene

Completed

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Lymphoma, T-Cell, Peripheral

Japan
Sandoz
Novartis Pharmaceuticals

Completed

GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma

Indolent B-cell Non-Hodgkin's Lymphoma

Japan
Eisai Inc.

Completed

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Lymphoma, T-cell, Peripheral | Lymphoma, T-cell, Cutaneous

Japan
Kyowa Kirin Co., Ltd.

Completed

Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15

Adult T-cell Leukemia-Lymphoma

Japan
Jichi Medical University
Takara Bio Inc.

Unknown

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Japan
HUYABIO International, LLC.
Quintiles, Inc.

Completed

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)

Adult T-Cell Lymphoma (ATL)

Japan
Pfizer

Active, not recruiting

BESPONSA Injection 1 mg Special Investigation

Acute Lymphocytic Leukemia

Japan
Japan Adult Leukemia Study Group

Unknown

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

Lymphoblastic Leukemia, Acute

Japan
Japan Adult Leukemia Study Group

Unknown

Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Lymphoblastic Leukemia, Acute

Japan
National Cancer Institute (NCI)

Completed

Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1

Human T-Lymphoma Virus Type I

United States, Jamaica, Japan
Bristol-Myers Squibb

Recruiting

Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy

Peripheral T-cell Lymphoma

Japan
Japan Adult Leukemia Study Group

Completed

Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

Japan
Takeda

Completed

Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"

Untreated CD30-Positive Hodgkin's Lymphoma

Japan
Mundipharma K.K.

Completed

Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

Japan
Spectrum Pharmaceuticals, Inc
Bayer

Completed

Zevalin Post-marketing Surveillance in Japan (ZEVALIN-DUI)

Non-Hodgkin's Lymphoma (NHL)

Japan
Bayer

Completed

Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan (ZEVALIN-SDUI)

Non-Hodgkin's Lymphoma (NHL)

Japan
Eisai Co., Ltd.

Completed

A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Japan
Solasia Pharma K.K.

Completed

A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)

Peripheral T-cell Lymphoma

Japan
Japan Clinical Oncology Group
Ministry of Health, Labour and Welfare, Japan

Terminated

Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)

Non-Hodgkin's Lymphoma

Japan
Celgene

Recruiting

Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)

Lymphoma Nonhodgkin

Japan
Pfizer

Completed

Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

Lymphoma, B-Cell

Japan
Bristol-Myers Squibb

Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan

Relapsed or Refractory T-cell Lymphomas

Japan
Genmab
AbbVie

Active, not recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL (EPCORE™ NHL-3)

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma

Japan
SymBio Pharmaceuticals

Completed

A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Japan
Takeda

Recruiting

A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma

Hodgkin Lymphoma

Japan
Novartis Pharmaceuticals

Recruiting

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

B-cell Non-Hodgkin Lymphoma (B-NHL) | B-cell Acute Lymphoblastic Leukemia (B-ALL)

Japan, Italy, Spain, Belgium, Singapore, France, United States, Israel
Takeda

Completed

Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"

Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other

Japan
SymBio Pharmaceuticals

Completed

A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Japan
Janssen Pharmaceutical K.K.

Completed

Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma, Mantle-cell

Japan
Eisai Co., Ltd.

Completed

E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

Peripheral T-Cell Lymphoma

Japan
Celgene

Completed

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

Adult T-Cell Leukemia-Lymphoma

Japan
Keio University

Terminated

Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

Japan
Celgene

Completed

A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

Japan
Incyte Corporation

Completed

A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)

Lymphoma

Japan
Institut de Recherches Internationales Servier
Kyowa Kirin Co., Ltd.; ADIR, a Servier Group company

Completed

A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Japan

3

Subscribe